SCHEMBL3282004

SCHEMBL3282004

O=C(Cc1ccc(F)c(F)c1)c1ccncc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.48
CYP17A1 P05093 1/20 0.46
CYP11B1 P15538 1/20 0.46
CYP11B2 P19099 1/20 0.46
PLOD2 O00469 2/20 0.44
PLOD3 O60568 2/20 0.44
PLOD1 Q02809 2/20 0.44
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2D6 P10635 2/20 0.43
CYP2C19 P33261 2/20 0.43
ALDH1A1 P00352 1/20 0.43
CYP2C9 P11712 1/20 0.43
HPGD P15428 1/20 0.43
HIF1A Q16665 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
LTA4H P09960 1/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
CES2 O00748 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5353997 0.83 NAMPT (0.51) NAMPTCYP17A1CYP11B1CYP11B2ALDH1A1
SCHEMBL1515699 0.83 MAPT (0.51) CYP3A4ALDH1A1HPGDHIF1AL3MBTL1
SCHEMBL38657578 0.81 RAB9A (0.62) CYP3A4HPGDL3MBTL1NPC1RAB9A
SCHEMBL1993655 0.81 L3MBTL1 (0.58) NAMPTPLOD2PLOD3PLOD1CYP1A2
SCHEMBL4091982 0.79 LOXL2 (0.47) NAMPTPLOD2PLOD3PLOD1CYP1A2
SCHEMBL6203734 0.78 ALDH1A1 (0.55) PLOD2PLOD3PLOD1CYP1A2CYP3A4
SCHEMBL6101952 0.77 RAB9A (0.66) NAMPTPLOD2PLOD3PLOD1CYP1A2
SCHEMBL1568038 0.76 L3MBTL1 (0.70) NAMPTCYP3A4L3MBTL1MAOB
SCHEMBL25902458 0.76 RAB9A (0.66) NAMPTNPC1RAB9AMAPK8
SCHEMBL5921849 0.75 PIK3CA (0.54) NAMPTPLOD2PLOD3PLOD1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2018364-B1 THERAPEUTIC FLUOROETHYL UREAS ALLERGAN INC (US) 2013-08-21 EP disclosed
US-7709507-B2 Therapeutic fluoroethyl ureas ALLERGAN, INC. (US) 2010-05-04 US disclosed
EP-2018364-A1 THERAPEUTIC FLUOROETHYL UREAS Allergan, Inc. (US) 2009-01-28 EP disclosed
WO-2007137029-A1 THERAPEUTIC FLUOROETHYL UREAS ALLERGAN, INC. (US) 2007-11-29 WO disclosed
US-20070270498-A1 THERAPEUTIC FLUOROETHYL UREAS ALLERGAN, INC. 2007-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270498-A1 THERAPEUTIC FLUOROETHYL UREAS SLC14A1, MAPT, UTS2R NAMPT 1924/4885CYP17A1 1948/4885CYP11B1 562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.